Almitrine

Almitrine (marketed as Duxil by Servier) is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews.

Almitrine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R07AB07 (WHO)
Identifiers
IUPAC name 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N'- diprop-2-enyl-1,3,5-triazine-2,4-diamine
CAS Number	27469-53-0 Y
PubChem CID	33887
DrugBank	DB01430 Y
ChemSpider	31235 Y
UNII	9A1222NBG4
KEGG	D07126 Y
ChEBI	CHEBI:53778 Y
ChEMBL	ChEMBL1183717 N
CompTox Dashboard (EPA)	DTXSID4057899
ECHA InfoCard	100.044.054
Chemical and physical data
Formula	C26H29F2N7
Molar mass	477.564 g·mol−1
3D model (JSmol)	Interactive image
Melting point	181 °C (358 °F)
SMILES Fc1ccc(cc1)C(c2ccc(F)cc2)N4CCN(c3nc(nc(n3)NC\C=C)NC\C=C)CC4
InChI InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33) Y Key:OBDOVFRMEYHSQB-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

The clinical efficacy of almitrine-raubasine combination therapy for age related cerebral disorders and functional rehabilitation after stroke has been reviewed by Allain and Bentué-Ferrer.[1] They summarize two studies in which almitrine-raubasine improved some symptoms significantly more than placebo, especially in vascular cases. Their paper also suggests that other studies have shown a beneficial effect of this compound on neurosensory vascular disorders, specifically chorioretinal dysfunctions (visual symptomatology) and vertigo associated with electronystagmographic modifications. This paper further claims that the dosage and tolerance of the compound have been confirmed in a French multi-center study of 5,361 outpatients.